{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial on the Effect of Intravenous Lignocaine Infusion on Intraoperative Desflurane Requirements"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "randomised 1:1 to receive either a bolus of 1.5 mg/kg of 2% lignocaine hydrochloride followed by an infusion of 1 mg/kg/h (Group A) or an equal volume of normal saline (Group B)."
      },
      "Participants": {
        "score": 2,
        "evidence": "Forty-eight patients aged 18-75 years, scheduled for laparoscopic cholecystectomy, appendicectomy, or ovarian cystectomy at Hospital Universiti Kebangsaan Malaysia"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised 1:1 to receive either a bolus of 1.5 mg/kg of 2% lignocaine hydrochloride followed by an infusion of 1 mg/kg/h (Group A) or an equal volume of normal saline (Group B)."
      },
      "Objective": {
        "score": 1,
        "evidence": "This randomised controlled trial investigated the impact of intravenous (IV) lignocaine infusion on intraoperative end-tidal desflurane (Et-Des) concentration"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the Et-Des concentration, measured every 10 minutes until skin closure."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated with allocation concealment using sealed envelopes."
      },
      "Blinding": {
        "score": 2,
        "evidence": "Both patients and clinicians were blinded."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Forty-eight patients aged 18-75 years"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Forty-seven patients were analysed (23 in Group A, 24 in Group B)."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Group A had a significantly lower Et-Des concentration (4.3% \u00b1 0.45%) compared to Group B (5.3% \u00b1 0.56%, p < 0.001)."
      },
      "Harms": {
        "score": 1,
        "evidence": "One adverse event of fast atrial fibrillation occurred in Group A."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT06064331."
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Supported by Azlina Masdar."
      }
    },
    "total_score": 22,
    "max_score": 25
  },
  "model": "gpt-4o"
}